Cortexyme Inc. Stock News

The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.

Another new drug candidate for the treatment of Alzheimer's disease failed miserably in a clinical trial.

Today, investors in CRTX stock lament a rather poor announcement from the company that a key clinical trial missed its primary endpoint. The post CRTX Stock: What to Know as Cortexyme Plummets 75% app

Cortexyme Inc (NASDAQ: CRTX) shares are trading lower after the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints. Cortexyme says they will present the additional top-line results f

An Alzheimer's disease trial failure was much worse than the company's relatively upbeat look forward suggests.

Shares of Cortexyme Inc. CRTX, -73.76% tumbled 72.7% in trading on Wednesday, the day after the company said a late-stage clinical trial evaluating its experimental Alzheimer's disease treatment faile

Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc (NASDAQ: CRTX) reported Phase 2/3 GAIN

Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge

Cortexyme has a unique hypothesis- that Alzheimer's disease (AD) is caused by a neurological infection with P. gingivalis. There is a surprising amount of data generated by the company and independent

CRTX is pursuing a highly speculative hypothesis that gingivitis plays a role in the pathogenesis of Alzheimer's Disease (AD). Top line results for AD Phase 2/3 trial expected mid-November; success wo

Screen capture via Cortexyme animation.  A Bigger Bubble Than The Late '90s

The stock price of Cortexyme Inc (NASDAQ: CRTX) increased 47.32%. This is why it happened.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors ar

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX).  Such investors are advised